HALO - J&J wins another FDA label expansion for multiple myeloma therapy July, 31 2024 08:51 AM Halozyme Therapeutics Inc. 2024-07-31 08:51:19 ET More on J&J, Genmab, Halozyme, etc. 4 Positives For Johnson & Johnson Johnson & Johnson: Seriously Undervalued At Peak Pessimism Johnson & Johnson Q2: Robust New Product Pipeline Most U.S. pharmas don't pay any U.S. income tax J&J talc bankruptcy plan appeal denied For further details see: J&J wins another FDA label expansion for multiple myeloma therapy